Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Bim-targeted cancer therapy: a link between drug action and underlying molecular changes Akiyama T; Dass CR; Choong PFMol Cancer Ther 2009[Dec]; 8 (12): 3173-80In the past few years, the pro-apoptotic molecule Bim has attracted increasing attention as a plausible target for tumor therapy. A variety of normal and pathological systems regulated by Bim, dependent on cell type, apoptotic stimulation, and chemotherapeutic agents, have been documented. Bim promotes anoikis of many tumor cells, such as lung cancer, breast cancer, osteosarcoma, and melanoma. Various chemotherapeutic agents use Bim as a mediating executioner of cell death. Hence, Bim suppression supports metastasis and chemoresistance. Imatinib, gefitinib, bortezomib, and Bim protein itself are spotlighted as current and future Bim-targeting therapeutic agents. The potential benefits of Bim-targeted therapies are selectivity of treatment for tumor cells and reduction in tumor-associated phenomena such as chemoresistance and metastasis. Thus, Bim-targeting therapies may provide more effective and unique tumor management modalities in future. This review article discusses all these issues.|Animals[MESH]|Antineoplastic Agents/pharmacology/*therapeutic use[MESH]|Apoptosis Regulatory Proteins/metabolism/*physiology[MESH]|Apoptosis/*drug effects[MESH]|Bcl-2-Like Protein 11[MESH]|Cytochromes c/metabolism[MESH]|Humans[MESH]|Membrane Proteins/metabolism/*physiology[MESH]|Mitochondria/drug effects/metabolism[MESH]|Models, Biological[MESH]|Neoplasms/*drug therapy/metabolism/physiopathology[MESH]|Proto-Oncogene Proteins/metabolism/*physiology[MESH]|Ubiquitination/drug effects[MESH] |